In new research, scientists at Washington University School of
Medicine in St. Louis have identified a cell growth pathway that is unusually
active in pediatric brain tumors known as gliomas. They previously identified
the same growth pathway as a critical contributor to brain tumor formation and
growth in neurofibromatosis-1 (NF1), an inherited cancer predisposition
syndrome.
"This suggests that the tools we've been developing to
diagnose and treat NF1 may also be helpful for sporadic brain tumors,"
says senior author David H. Gutmann, MD, PhD, the Donald O. Schnuck Family
Professor of Neurology.
The findings appear Dec. 1 in Genes and Development.
NF1 is among the most common tumor predisposition syndromes, but
it accounts for only about 15 percent of pediatric low-grade gliomas known as
pilocytic astrocytomas. The majority of these brain tumors occur sporadically
in people without NF1.
Earlier research showed that most sporadic pilocytic astrocytomas
possess an abnormal form of a signaling protein known as BRAF. In tumor cells,
a piece of another protein is erroneously fused to the business end of BRAF.
Scientists suspected that the odd protein fusion spurred cells to
grow and divide more often, leading to tumors. However, when they gave mice the
same aberrant form of BRAF, they observed a variety of results. Sometimes
gliomas formed, but in other cases, there was no discernible effect or a brief
period of increased growth and cell division. In other studies, the cells grew
old and died prematurely.
Gutmann, director of the Washington University Neurofibromatosis
Center, previously showed that mouse NF1-associated gliomas arise from certain
brain cells.
According to Gutmann, the impact of abnormal NF1 gene function on
particular cell types helps explain why gliomas are most often found in the
optic nerves and brainstem of children with NF1 -- these areas are where the
susceptible cell types reside.
With that in mind, Gutmann and his colleagues tested the effects
of the unusual fusion BRAF protein in neural stem cells from the cerebellum,
where sporadic pilocytic astrocytomas often form, and in cells from the cortex,
where the tumors almost never develop.
"Abnormal BRAF only results in increased growth when it is
placed in neural stem cells from the cerebellum, but not the cortex,"
Gutmann says. "We also found that putting fusion BRAF into mature glial
cells from the cerebellum had no effect."
When fusion BRAF causes increased cell proliferation, postdoctoral
fellows Aparna Kaul, PhD and Yi-Hsien Chen, PhD, showed that it activates the
same cellular growth pathway, called mammalian target of rapamycin (mTOR), that
is normally also controlled by the NF1 protein. An extensive body of research
into the mTOR pathway already exists, including potential treatments to
suppress its function in other forms of cancer.
"We may be able to leverage these insights and our previous
work in NF1 to improve the treatment of these common pediatric brain tumors,
and that's very exciting," Gutmann says.
Gutmann and his colleagues are now working to identify more of the
factors that make particular brain cells vulnerable to the tumor-promoting
effects of the NF1 gene mutation and fusion BRAF. They are also developing
animal models of sporadic pilocytic astrocytoma for drug discovery and testing.
Source:
The above story is reprinted from materials provided by Washington University School of Medicine.
The original article was written by Michael C. Purdy.
Note: Materials may be edited for content and length.
For further information, please contact the source cited above.
Journal Reference:
1. Kaul A, Chen Y-H, Emnett RJ, Dahiya S, Gutmann
DH.Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial
cell growth in a cell type-specific and mTOR-dependent manner.. Genes
& Development, Dec. 1, 2012
Disclaimer: This article is not intended to provide
medical advice, diagnosis or treatment. Views expressed here do not necessarily
reflect those of Eagle Group or its staff.
0 comments:
Post a Comment